Advertisement
Canada markets open in 4 hours 37 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7330
    +0.0007 (+0.09%)
     

  • CRUDE OIL

    83.80
    +0.23 (+0.28%)
     

  • Bitcoin CAD

    87,779.68
    +800.64 (+0.92%)
     

  • CMC Crypto 200

    1,389.28
    -7.25 (-0.52%)
     

  • GOLD FUTURES

    2,360.70
    +18.20 (+0.78%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,744.75
    +177.25 (+1.01%)
     

  • VOLATILITY

    15.55
    +0.18 (+1.17%)
     

  • FTSE

    8,108.28
    +29.42 (+0.36%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6819
    -0.0002 (-0.03%)
     

Compared to Estimates, LabCorp (LH) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·2 min read

LabCorp (LH) reported $3.78 billion in revenue for the quarter ended March 2023, representing a year-over-year decline of 3.1%. EPS of $3.82 for the same period compares to $6.11 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $3.75 billion, representing a surprise of +0.87%. The company delivered an EPS surprise of -4.26%, with the consensus EPS estimate being $3.99.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how LabCorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Drug Development: $1.40 billion versus $1.52 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -4% change.

  • Revenues- Diagnostics: $2.38 billion versus the four-analyst average estimate of $2.28 billion. The reported number represents a year-over-year change of -2.9%.

  • Adjusted Operating Income- Drug Development: $123.90 million compared to the $185.31 million average estimate based on three analysts.

  • Adjusted Operating Income- Diagnostics: $441.50 million compared to the $558.66 million average estimate based on three analysts.

View all Key Company Metrics for LabCorp here>>>

Shares of LabCorp have returned +5.8% over the past month versus the Zacks S&P 500 composite's +4.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research